Next Article in Journal
Gastric Cancer Stem Cells: Current Insights into the Immune Microenvironment and Therapeutic Targets
Next Article in Special Issue
The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease
Previous Article in Journal
Early Exposure to THC Alters M-Cell Development in Zebrafish Embryos
Previous Article in Special Issue
The Mechanism of Bisphenol A Atherogenicity Involves Apolipoprotein A-I Downregulation through NF-κB Activation
Open AccessArticle

Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia

1
Cardiovascular Biochemistry Group, Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain
2
Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Valles, Spain
3
Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
4
CIBER of Diabetes and Metabolic Diseases (CIBERDEM), 28029 Madrid, Spain
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Biomedicines 2020, 8(1), 6; https://doi.org/10.3390/biomedicines8010006
Received: 10 December 2019 / Revised: 2 January 2020 / Accepted: 3 January 2020 / Published: 6 January 2020
Lipoprotein characteristics were analyzed in familial combined hyperlipidemia (FCH) patients before and after statin treatment. Twenty-six FCH patients were classified according to the presence (HTG group, n = 13) or absence (normotriglyceridemic (NTG) group, n = 13) of hypertriglyceridemia. Fifteen healthy subjects comprised the control group. Lipid profile, inflammation markers, and qualitative characteristics of lipoproteins were assessed. Both groups of FCH subjects showed high levels of plasma C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and apolipoprotein J. Statins reverted the increased levels of Lp-PLA2 and CRP. Lipoprotein composition alterations detected in FCH subjects were much more frequent in the HTG group, leading to dysfunctional low-density lipoproteins (LDL) and high-density lipoproteins (HDL). In the HTG group, LDL was smaller, more susceptible to oxidation, and contained more electronegative LDL (LDL(-)) compared to the NTG and control groups. Regarding HDL, the HTG group had less Lp-PLA2 activity than the NTG and control groups. HDL from both FCH groups was less anti-inflammatory than HDL from the control group. Statins increased LDL size, decreased LDL(-), and lowered Lp-PLA2 in HDL from HTG. In summary, pro-atherogenic alterations were more frequent and severe in the HTG group. Statins improved some alterations, but many remained unchanged in HTG. View Full-Text
Keywords: familial combined hyperlipidemia; lipoproteins; lipoprotein function; inflammation; triglycerides familial combined hyperlipidemia; lipoproteins; lipoprotein function; inflammation; triglycerides
Show Figures

Figure 1

MDPI and ACS Style

Puig, N.; Miñambres, I.; Benítez, S.; Gil, P.; Grau-Agramunt, M.; Rivas-Urbina, A.; Pérez, A.; Sánchez-Quesada, J.L. Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia. Biomedicines 2020, 8, 6.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop